[Effect of recombinant human granulocyte-macrophage colony stimulating factor on wound healing in patients with deep partial thickness burn].
OBJECTIVE
To evaluate the efficacy and safety of recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) hydrogel in wound healing in patients with deep partial thickness burn.


METHODS
The study was a multicenter, randomized, double-blind, placebo-controlled parallel clinical trial. Three hundred and twenty-one patients (302 cases finally fulfilled the protocol) with deep partial thickness burn were divided into A group (n = 200, with treatment of rhGM-CSF hydrogel, 100 microg/10 g/100 cm2/d), C group (n = 102,with treatment of placebo). Side-effect, systemic condition, wound healing time, wound healing rate, and total effective rate at different time points were observed.


RESULTS
There were no obvious differences in vital signs, wound secretion, wound edge reaction, blood and urine routine, liver and kidney function between two groups (P > 0.05). No side-effect was observed. The median wound healing time was 17 days in A group, which was obviously shorter than that in C group (20 days, P < 0.01). The mean wound healing rate in A group was 24.5%, 70.5%, 95.3%, 99.6% respectively on 8th, 14th, 20th, 28th day after treatment, which were obviously higher than that in C group (15.1%, 51.4%, 84.6%, 97.1%, respectively, P < 0.01). The total effective rates in A group on 8th, 14th, 20th day after treatment were also higher than that in C group (P < 0.01).


CONCLUSIONS
rhGM-CSF hydrogel can significantly accelerate wound healing in patients with deep partial thickness burn with certain safety.
Wang
Zhi-Yong
ZY
Department of Burns, Ruijin Hospital, Medical College of Shanghai JiaoTong University, Shanghai 200025, PR China.
Zhang
Qin
Q
Liao
Zhen-Jiang
ZJ
Han
Chun-Mao
CM
Lv
Guo-Zhong
GZ
Luo
Cheng-Qun
CQ
Chen
Jiong
J
Yang
Shi-Xin
SX
Yang
Xiao-Dong
XD
Liu
Qun
Q
D002056:Burns / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020100:Hydrogels / Q000627:therapeutic use*; D008297:Male; D010919:Placebos; D011994:Recombinant Proteins; D014945:Wound Healing
D020100:Hydrogels; D010919:Placebos; D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor